Nurix Therapeutics, Inc. NRIX Available-for-Sale Debt Securities - Unrealized Loss Position
Available-for-Sale Debt Securities - Unrealized Loss Position at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s available-for-sale debt securities - unrealized loss position.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s available-for-sale debt securities - unrealized loss position?
- Nurix Therapeutics, Inc. (NRIX) reported available-for-sale debt securities - unrealized loss position of $32K in Q4 2025.
- How has Nurix Therapeutics, Inc.'s available-for-sale debt securities - unrealized loss position changed year-over-year?
- Nurix Therapeutics, Inc.'s available-for-sale debt securities - unrealized loss position decreased by 20.0% year-over-year, from $40K to $32K.
- What does available-for-sale debt securities - unrealized loss position mean?
- This represents the aggregate fair value of all available-for-sale debt securities currently held at a price lower than their amortized cost. It provides a comprehensive view of the total unrealized loss exposure within the investment portfolio. This metric is critical for assessing the overall health and market sensitivity of the company's treasury assets.